Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended March 31, 2023 and 2022 is as follows:

	Three Months Ended March 31, 2023
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	1,357	$	2,578		$	-			$	3,935
Gross profit		-			885		1,047			-				1,932
Direct expenses		40,162			344		3,009			11,155				54,670
Segment contribution	$	(40,162	)	$	541	$	(1,962	)		(11,155	)			(52,738	)
Indirect expenses										11,132		(a)		11,132
Loss from operations													$	(63,870	)
(a) Components of other
Change in fair value of contingent consideration liability										(18,932	)
Change in fair value of contingent stock consideration										(110	)
Goodwill impairment										29,633
Amortization										541
Total other									$	11,132

	Three Months Ended March 31, 2022
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net sales	$	-		$	1,283		$	4,652	$	-			$	5,935
Gross profit		-			335			1,574		-				1,909
Direct expenses		21,213			626			1,459		13,270				36,568
Segment contribution		(21,213	)		(291	)		115		(13,270	)			(34,659	)
Indirect expenses										6,955		(b)		6,955
Loss from operations													$	(41,614	)
(b) Components of other
Change in fair value of contingent consideration liability										4,849
Change in fair value of contingent stock consideration										1,565
Amortization										541
Total other									$	6,955